Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee (PRAC) of Vaxzevria (previously COVID-19 Vaccine AstraZeneca) and thromboembolic events
Table of contents
Location: Virtual meeting
EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events by EMA’s safety committee (PRAC) on 7 April 2021.
- Emer Cooke (Executive Director)
- Sabine Straus (Chair of PRAC)
- Peter Arlett (Head of Data Analytics and Methods Task Force)
The press briefing will be moderated by Ms Marie-Agnes Heine (Head of Communication). The press briefing will be held in English.
To view the broadcast please ensure you meet the YouTube requirements.
To view the video in the highest quality, click on the 'Settings' symbol in the right-hand corner of the video player and select '720p' or a higher resolution.